Synoptical view

    Truffle investment
    € 28M

Management team

Board of directors

In summary

Affluent Medical is a French medical company specializing in innovative, next-generation, minimally invasive implants

To date, Affluent Medical has developed four medical devices in the preclinical or clinical phase:

  • EPYGON: The first transcatheter mitral valve to restore natural blood flow and save the ventricle. Currently, 4 million patients in Europe, the United States and Asia suffer from severe mitral valve regurgitation without access to optimal therapies.

  • KALIOS: The first fully adjustable mitral valve repair medical device designed to effectively meet the needs of mitral insufficiency patients, representing 1% of the world population.

  • ARTUS: The first electronically activatable artificial sphincter to treat urinary incontinence. 1 in 4 adults suffer from stress urinary incontinence, with a high prevalence among women.

  • KARDIOZIS: The first endovascular prosthetic technology to prevent endoleaks and reduce aneurysm size in the abdominal aortic aneurysm that affects 5 to 10% of men between the ages of 65 and 80.

They talk about it

Affluent Medical has recently made significant progress and is now entering an intense phase of clinical trials. Our renewed management team, including key additional skills, will enable the Group to strengthen and secure the validation of these products for regulatory approval.



Next start-up